Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Citius Pharma (CTXR)
:CTXR
RESEARCH TOOLSreports
CTXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.47 - $26.77
Previous CloseN/A
Volume111.57K
Average Volume (3M)156.73K
Market Cap
$15.90M
Enterprise Value$91.73M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 08, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding8,593,433
10 Day Avg. Volume271,191
30 Day Avg. Volume156,727
Standard Deviation0.27
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap5.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$9.00Price Target Upside386.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMino-Lok achieved its primary endpoint in the P3 study, significantly delaying or preventing catheter failure compared to the standard of care.
Regulatory GuidanceCitius Pharma has received clear, constructive, and actionable guidance from the FDA for the path to NDA submission for Mino-Lok.
Bears Say
Revenue RiskTimelines for the NDA submission of Mino-Lok are uncertain, leading to an increase in the revenue risk adjustment.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTXR FAQ
What was Citius Pharma’s price range in the past 12 months?
Citius Pharma lowest stock price was $1.47 and its highest was $26.77 in the past 12 months.
What is Citius Pharma’s market cap?
Citius Pharma’s market cap is $15.90M.
When is Citius Pharma’s upcoming earnings report date?
Citius Pharma’s upcoming earnings report date is May 08, 2025 which is in 75 days.
How were Citius Pharma’s earnings last quarter?
Citius Pharma released its earnings results on Feb 14, 2025. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.365 by $0.065.
Is Citius Pharma overvalued?
According to Wall Street analysts Citius Pharma’s price is currently Undervalued.
Does Citius Pharma pay dividends?
Citius Pharma does not currently pay dividends.
What is Citius Pharma’s EPS estimate?
Citius Pharma’s EPS estimate is 0.33.
How many shares outstanding does Citius Pharma have?
Citius Pharma has 8,593,433 shares outstanding.
What happened to Citius Pharma’s price movement after its last earnings report?
Citius Pharma reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.365. Following the earnings report the stock price went down -8.178%.
Which hedge fund is a major shareholder of Citius Pharma?
Currently, no hedge funds are holding shares in CTXR
---
Citius Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (386.49% Upside)
$9.00 (386.49% Upside)
Blogger Sentiment
Bullish
CTXR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 12.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.13%
12-Months-Change
Fundamentals
Return on Equity
-52.85%
Trailing 12-Months
Asset Growth
23.93%
Trailing 12-Months
Company Description
Citius Pharma
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
---
CTXR Stock 12 Month Forecast
Average Price Target
$9.00
▲(386.49% Upside)
Technical Analysis
Best Analysts Covering CTXR
1 Year
1 Year Success Rate
10/26 ratings generated profit
1 Year Average Return
-0.04%
upgraded a buy rating 2 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -0.04% per trade.
---